Sign In
Buy EVLO
$0.0001
+0 (+0%)
At Close: Jun 22, 2026
Stock Traders Buy Large Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)
01:09am, Thursday, 02'nd Apr 2026
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 1,885 put options on the stock. This represents an increa
Head to Head Review: Evelo Biosciences (NASDAQ:EVLO) vs. Silverback Therapeutics (NASDAQ:SBTX)
01:00am, Thursday, 19'th Mar 2026
Profitability This table compares Silverback Therapeutics and Evelo Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Silverback Therapeuti
Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)
01:42am, Thursday, 05'th Feb 2026
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 1,885 put options on the company. This represents an i
Stock Traders Buy High Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)
03:32am, Thursday, 25'th Dec 2025
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 1,885 put options on the stock. This is an increase of 1,101% com
Evelo Biosciences (NASDAQ:EVLO) vs. Vincerx Pharma (NASDAQ:VINC) Financial Analysis
01:59am, Thursday, 18'th Dec 2025
Insider and Institutional Ownership 44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 15.6% of Vi
Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO)
02:12am, Thursday, 27'th Nov 2025
Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 1,885 put options on the company. This is an inc
Analyzing Evelo Biosciences (NASDAQ:EVLO) & Antibe Therapeutics (OTCMKTS:ATBPD)
03:19am, Friday, 31'st Oct 2025
Valuation and Earnings This table compares Antibe Therapeutics and Evelo Biosciences"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Sh
EVLO to Provide Dominion Energy With Safety Enhanced Energy Storage Systems
08:00am, Wednesday, 20'th Nov 2024
MONTRÉAL--(BUSINESS WIRE)--EVLO Energy Storage Inc. (EVLO), a fully integrated battery energy storage systems (BESS) provider and wholly owned subsidiary of Hydro-Québec, announces a major achieveme
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
08:15am, Friday, 20'th Oct 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
12:47pm, Wednesday, 18'th Oct 2023
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
Evelo Biosciences shares tank 46% after trial failure
09:00am, Tuesday, 17'th Oct 2023
Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its next-generation drug, EDP2939. A resounding
Evelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goal
07:29am, Tuesday, 17'th Oct 2023
Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
07:00am, Tuesday, 17'th Oct 2023
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -
Evelo Biosciences: May Be Worth A Small, Highly Speculative Long Position Considering Upcoming Psoriasis Phase 2 Results
05:08pm, Friday, 25'th Aug 2023
Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or break the company. Prior failure of EVLO's platform i
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
07:30am, Monday, 14'th Aug 2023
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructured and reduced secured debt with Hor
